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Abstract
Objective To determine the effectiveness of intensive structured care
to optimise blood pressure control based on individual absolute risk
targets in primary care.
Design Pragmatic multicentre randomised controlled trial.
SettingGeneral practices throughout Australia, except Northern Territory,
2009-11.
Participants Of 2185 patients from 119 general practices who were
eligible for drug treatment for hypertension according to national
guidelines 416 (19.0%) achieved their individual blood pressure target
during a 28 day run-in period of monotherapy. After exclusions, 1562
participants not at target blood pressure (systolic 150 (SD 17) mm Hg,
diastolic 88 (SD 11) mm Hg) were randomised (1:2 ratio) to usual care
(n=524) or the intervention (n=1038).
Intervention Computer assisted clinical profiling and risk target setting
(all participants) with intensified follow-up and stepwise drug titration
(initial angiotensin receptor blocker monotherapy or two forms of
combination therapy using angiotensin receptor blockers) for those
randomised to the intervention. The control group received usual care.
Main outcome measures The primary outcome was individual blood
pressure target achieved at 26 weeks. Secondary outcomes were change
in mean sitting systolic and diastolic blood pressure, absolute risk for
cardiovascular disease within five years based on the Framingham risk
score, and proportion and rate of adverse events.
Results On an intention to treat basis, there was an 8.8% absolute
difference in individual blood pressure target achieved at 26 weeks in
favour of the intervention group compared with usual care group (358/988
(36.2%) v 138/504 (27.4%)): adjusted relative risk 1.28 (95% confidence
interval 1.10 to 1.49, P=0.0013). There was also a 9.5% absolute
difference in favour of the intervention group for achieving the classic
blood pressure target of ≤140/90 mm Hg (627/988 (63.5%) v 272/504
(54.0%)): adjusted relative risk 1.18 (1.07 to 1.29, P<0.001). The
intervention group achieved a mean adjusted reduction in systolic blood
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pressure of 13.2 mm Hg (95% confidence interval −12.3 to −14.2 mm
Hg) and diastolic blood pressure of 7.7 mm Hg (−7.1 to −8.3 mm Hg) v
10.1 mm Hg (−8.8 to 11.3 mm Hg) and 5.5 mm Hg (−4.7 to −6.2 mm
Hg) in the usual care group (P<0.001). Among 1141 participants in whom
five year absolute cardiovascular risk scores were calculated from
baseline to the 26 week follow-up, the reduction in risk scores was
greater in the intervention group than usual care group (14.7% (SD 9.3%)
to 10.9% (SD 8.0%); difference −3.7% (SD 4.5%) and 15.0% (SD 10.1%)
to 12.4% (SD 9.4%); −2.6% (SD 4.5%): adjustedmean difference −1.13%
(95% confidence interval −0.69% to −1.63%; P<0.001). Owing to adverse
events 82 (7.9%) participants in the intervention group and 10 (1.9%)
in the usual care group had their drug treatment modified.
Conclusions In a primary care setting intensive structured care resulted
in higher levels of blood pressure control, with clinically lower blood
pressure and absolute risk of future cardiovascular events overall and
with more people achieving their target blood pressure. An important
gap in treatment remains though and applying intensive management
and achieving currently advocated risk based blood pressure targets is
challenging.
Introduction
Although hypertension is a readily detectable and modifiable
condition it is responsible for more deaths worldwide than any
other cardiovascular risk factor, including tobacco use, obesity,
and lipid disorders.1 In the United States, of all modifiable risk
factors hypertension has been associated with the greatest
population attributable risk for all cause mortality (30%) and
deaths from cardiovascular disease (40%).2 Epidemiological
studies suggest a relation between raised blood pressure and
increased risk of cardiovascular events.3 Large scale clinical
trials examining the efficacy of a broad range of
antihypertensives found a consistent and continuous reduction
in cardiovascular risk (primary or secondary events and across
all age groups) according to the baseline values and magnitude
of change in both systolic and diastolic blood pressure.3
Traditionally, the ideal blood pressure target has been ≤140/90
mmHg for those aged less than 80 years and these are reflected
in current guidelines from the National Institute for Health and
Clinical Excellence in the United Kingdom.4 The introduction
of absolute risk profiling for primary prevention purposes4 5 and
more stringent, individualised blood pressure targets for higher
risk groups such as people with type 2 diabetes or more
advanced forms of cardiovascular disease6 7 has provided
clinicians in other regions of the world with a challenge in
meeting these targets. Considering the recent debate on whether
more stringent blood pressure targets fail to provide
cardioprotection and perhaps even confer harm at blood pressure
levels approaching 110/75mmHg8 it is likely that more stringent
blood pressure targets will be subject to further consideration.
Regardless of recommended blood pressure targets, however,
the translation of potential benefits from clinical trials to the
real life management of hypertension (much of which occurs
in primary care) is less than ideal. Many people prescribed
antihypertensive treatment have a blood pressure >140/90 mm
Hg.9 A key component of effective translation in the primary
care setting seems to be the application of structured
programmes to apply antihypertensive treatments by a rigorous
stepped care approach10 to overcome the common phenomenon
of prescription resistance11 (whereby clinicians are reluctant to
up-titrate existing drug treatment or prescribe additional
antihypertensive agents) and to achieve better individual blood
pressure control. For example, nurse led interventions that
comprise a structured care algorithm are associated with greater
reductions in blood pressure levels than usual care overall.12
Few studies, however, have specifically tested the application
of structured care in the setting of more stringent, risk based
blood pressure targets in a large and diverse range of general
practices—that is, small to large clinics and those with and
without practice nurses to implement structured care.
As described elsewhere,13 the Valsartan Intensified Primary
carE Reduction of Blood Pressure (VIPER-BP) study was a
pragmatic, multicentre, randomised trial evaluating the clinical
effectiveness and overall safety of a more intensive and
structured approach to optimising blood pressure control in a
group of people with persistently high blood pressure in a real
world primary care setting.
In a typical cohort of primary care patients with suboptimal
blood pressure (individualised target according to their risk
profile6), we hypothesised that a greater proportion of those
randomised to the intervention would achieve individualised
blood pressure control at the end of 26 weeks compared with
those randomised to usual care.
Methods
The Australian universal health insurance scheme (Medicare)
provides citizens with free access to public hospitals and
reimbursed access (70% of services with no co-payment) to a
widespread network of primary care or general practice clinics.
A parallel system, the Pharmaceutical Benefits Scheme, provides
subsidised drug treatment to all Australians, with capped
payments for those with a chronic illness; most prescriptions
for drugs being generated by general practitioners managing
people with chronic conditions such as hypertension.
Participants
Study participants were recruited by 260 general practitioners
from 119 general practices distributed throughout every state
and territory of Australia except the sparsely populated Northern
Territory. People routinely managed by these doctors were
potentially eligible to participate if they were aged 18 or more,
had a diagnosis of hypertension requiring active drug treatment
according to guidelines, and consented to participate. We
excluded people who had a mean initial systolic blood pressure
of 180 mm Hg or more while sitting, were prescribed three or
more antihypertensives; had moderate to severe renal disease
(clinical diagnosis or estimated glomerular filtration rate <60
mL/min/1.73m2), or had contraindications to angiotensin
receptor blockers, calcium channel blockers, or thiazide
diuretics. Recruitment took place from July 2009 to December
2010, with follow-up completed in July 2011.
Study design
This was an open label, two arm, randomised trial comparing
an intensive blood pressure management strategy with usual
care (control).13 Randomisation was by computer generated,
group assignment stratified according to nominated blood
pressure target (three strata) and block randomisation (units of
12) per general practitioner. An independent data management
team at Baker IDI coordinated a standardised protocol for
randomising participants over the telephone. Participants were
assigned to the groups using a prespecified ratio of 1:2 for usual
care versus intervention (with a further ratio of 1:2 within the
intervention arm to assign participants to amonotherapy strategy
and to two possible combined treatment strategies). Quality
control of the sites and general practitioners was achieved by
visits before randomisation and at study end. The study was
independently monitored by routine visits, and case report forms
were verified against clinical records for 20% of patients. We
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used standardised operating procedures for data queries and
management. All queries were resolved by the time the study
dataset was locked and no further changes were permitted.
Figure 1⇓ provides a graphical representation of the study
timelines.
Study entry
Eligible participants underwent baseline assessment, including
determination of absolute cardiovascular risk.5 On the basis of
this assessment, we identified target risk factor measures
(including blood pressure, lipid levels, exercise levels, smoking
status, and body mass index) for each participant according to
national guidelines.6 A computer program developed by Baker
IDI enabled clinical profiling in all participants and subsequent
management in intervention patients (see appendix I in the
supplementary file). Eligible participants began a standard 28
day run-in period of treatment with open label, oral valsartan
80 mg daily, with a mandatory blood pressure check 14 days
after the start of treatment to determine the need for immediate
(rescue) randomisation if systolic blood pressure was ≥180mm
Hg or clinically indicated. We then randomised into the study
those who did not achieve their prespecified blood pressure
target within this run-in period or were not specifically
withdrawn or lost to follow-up (blinded allocation).
Blood pressure measurement
Throughout the study we used a standardised protocol based on
national guidelines to record blood pressure measurements.6
After participants had rested for at least five minutes and while
theywere seatedwe obtained three blood pressuremeasurements
separated by one minute intervals using an appropriate sized
cuff and a calibrated, semiautomated oscillometric device
approved by the Therapeutic Goods Administration of Australia.
We defined aberrant measurements as those where the lowest
reading was 10 mm Hg or more for systolic blood pressure or
5 mmHg or more for diastolic blood pressure below the highest
of the three seated readings. If this occurred, the participant was
rested for three minutes and the procedure repeated. Given the
size and nature of the study, it was impractical to obtain
independent, blinded blood pressure levels. Nominated study
staff at each site (general practitioner or practice nurse) verified
the blood pressure measurements by an independent audit of
the clinical details in the case records, outputs from the blood
pressure monitor, and the computer decision tool.
Usual care
For those assigned to usual care, we asked general practitioners
to follow their usual pattern of clinic visits and treatment
strategies (no restriction on prescribed drugs) to achieve the
individualised blood pressure target and other prevention targets
identified during the run-in phase; the only mandatory study
visits were at weeks 6 (a typically brief 10-15 minute
consultation) and 26 (final comprehensive evaluation). We
explicitly acknowledged that this was an enhanced form of usual
care given that the participants had already been subject to
clinical profiling and had an identified blood pressure target
and their doctors potentially had knowledge of the intervention
(with the inherent problem of contamination).
Study intervention
Those allocated to the intervention arm followed an intensive
stepped programme of management, with mandatory visits to
their doctor at weeks 6, 10, 14, and 18 after randomisation to
review their blood pressure and to adjust their treatment if
needed according to prespecified algorithms (see appendix II
in the supplementary file). Typically, these consultations lasted
10-15 minutes (about 60 minutes in total) in addition to the time
taken for clinical profiling at baseline. Reflecting contemporary
treatment options for the management of hypertension, different
drug pathways were mandated (initial monotherapy with
valsartan 160 mg or combined with hydrochlorothiazide or
amlodipine, as single combined pills). Scheduling of visits and
up-titration of drug treatment was guided by the same computer
program developed by Baker IDI to facilitate the initial risk
profiling and management. A final clinic visit for clinical
re-evaluation was scheduled at 26 weeks.
Study endpoints
The primary endpoint was the percentage of participants who
achieved their individualised blood pressure target according
to national guidelines6 during 26 weeks of follow-up (using last
recorded blood pressure for intention to treat analyses). These
stringent blood pressure targets, which have been rarely
examined for feasibility in a controlled trial, are ≤125/75 mm
Hg if a patient has proteinuria, ≤130/80 mm Hg if end organ
damage is present (including any form of cardiovascular disease,
diabetes, or microalbuminuria), and the classic target of ≤140/90
mm Hg for those without evidence of the other two criteria.
Key secondary endpoints included change in mean sitting
systolic and diastolic blood pressure and absolute risk for
cardiovascular disease within five years based on the
Framingham risk score5 (where applicable). Secondary endpoints
also included the type and rate of adverse events potentially
attributable to antihypertensive treatment, and serious adverse
events including all cause mortality and fatal and non-fatal
cardiovascular events—for example, acutemyocardial infarction,
stroke, and heart failure. Several other secondary endpoints will
be the subject of future or expanded reports, including changes
in quality of life, depression, self care behaviours, and evidence
of end organ damage (including electrocardiographic evidence
of left ventricular hypertrophy and newly detected proteinuria).
Study power
We largely met the study targets for overall recruitment and
number of participants entering the run-in phase. Based on the
combination of a strong potential for interventional
contamination, balanced against the need to establish clinically
significant differences between the two groups, the study was
initially powered to detect a minimum absolute difference of
7% between the groups for the primary endpoint.13 As
proportionately more patients achieved blood pressure control
during the study run-in and thus the number of randomised
participants was reduced, we recalculated that a total randomised
cohort of more than 1500 participants would still provide
sufficient study power to detect a minimum 8% difference
between groups with more than 85% study power (two sided α
level of 0.05 and adjusting for 2:1 randomisation for study
intervention versus usual care).13
Statistical analyses
The study statistician (on behalf of the clinical safety and
efficacy committee) independently analysed the data according
to a prospectively designed statistical analysis plan. If blood
pressure values were missing at 26 weeks, we carried forward
the last recorded blood pressure measurement after
randomisation for primary endpoint analysis. Baseline and
outcome data were analysed using SPSS for Windows version
19.0. Continuous data are presented as means (standard
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deviations) or medians (interquartile ranges). Categorical data
are presented as percentages.
We carried out efficacy analyses on an intention to treat
population, consisting of all participants randomised to the
intervention arm or to the usual care arm and who had at least
one recorded blood pressure measurement after randomisation.
Analyses were based on the treatment group to which the
participant was randomised.We compared the primary endpoint
measure (blood pressure control at week 26) between the study
groups using a log binomial generalised linear model with
stratification status at randomisation as a covariate. Stratification
status was fit as a categorical variable with the three blood
pressure target groups (≤125/75 mm Hg, ≤130/80 mm Hg, and
≤140/90 mm Hg) based on the participant’s clinical profile.
Change in systolic and diastolic blood pressure from baseline
to 26 weeks were each analysed by analysis of covariance, with
treatment group and stratification status as factors and mean
baseline blood pressure as a covariate. We also describe the
proportion and rate of adverse events (per participant).
Results
Overall, 2337 participants (1381 men (59.1%), mean age 58
(SD 12) years) with hypertension from 119 general practices
were enrolled into the study; 2185 participants from 114
practices subsequently started the run-in phase of initial
treatment (valsartan 80 mg/day for 14-28 days, fig 2⇓). (The
figure in appendix II in the supplementary file shows a
simplified flow chart of study activity and interventions
according to group randomisation, including the initial phase
of clinical profiling of all participants who entered the run-in
phase of the study, and the two study arms after randomisation.)
Of those who entered the run-in phase, 1329 (60.8%) had
pre-existing hypertension and had been treated for a median of
5 (interquartile range 2-10) years. Previous treatment, which
was stopped on entry to the study, comprised monotherapy with
either angiotensin converting enzyme inhibitors or angiotensin
receptor blockers (n=907, 68.2%), a calcium channel antagonist
(n=233, 17.5%), or combination antihypertensive treatment
(n=259, 19.5%). The initial blood pressure target for these 2185
participants was ≤125/75 mmHg in 330 (15.1%), ≤130/80 mm
Hg in 993 (45.4%), and ≤140/90mmHg in 862 (39.5%). During
the run-in phase, 416 (19.0%) participants reached their initial
prespecified blood pressure target; comprising 20 (6.7%) of
those with a preliminary blood pressure target of ≤125/75 mm
Hg, 128 (12.9%) with ≤130/80 mm Hg, and 268 (31.1%) with
≤140/90 mm Hg. A further 207 (9.5%) participants withdrew
from the study (56 (2.6%) experienced an adverse event) and
were not randomised (fig 2).
Table 1⇓ shows the baseline characteristics of the 1562
participants randomised to the usual care group (n=524, 33.5%)
or intervention group (n=1038, 66.5%); 360 (23.0%) participants
in the intervention group were randomised to the monotherapy
arm and 678 (43.4%) to the combination therapy arm. The
proportion of patients treated for hypertension before the study
run-in phase (40% with angiotensin converting enzyme
inhibitors, 20% with an angiotensin receptor blocker, and 21%
with combination therapy including a calcium antagonist or
diuretic) had increased to 66.9%, with little difference between
the groups. The groups were well matched for clinical and
personal characteristics and prespecified blood pressure targets.
At randomisation, 219 (14.0% with equal proportions in each
group) were assigned to a blood pressure target that differed
from the recommended (automated) clinical profile; these
reflected general practitioners’ discretion for a mostly higher
blood pressure target than recommended. An endpoint blood
pressure was recorded in 504/524 participants in the usual care
group and 988/1038 in the intervention group, at any time point
after randomisation.
Patterns of blood pressure management
Drug treatment after randomisation was recorded in 501
participants (95.6%) in the usual care arm and 991 (95.5%) in
the intervention arm. In the intervention group, attendance
(within 14 days) at scheduled visits varied from 79.9-91.0%;
the highest attendance being at six weeks (compared with 91.4%
in the usual care group, table 2⇓). Overall, participants in the
usual care group had 854 clinic reviews (mean 1.7 visits) after
randomisation compared with 3477 in the intervention group
(mean 3.5 visits). Figures in appendix II in the supplementary
file show the (complex) pattern of prescribing in the usual care
group and the composite treatment groups comprising the
intervention group. At randomisation, most participants in the
intervention arm were prescribed their per protocol treatment:
334/360 (92.8%)monotherapy (valsartan 160mg daily), 228/250
(91.2%) hydrochlorothiazide combination therapy (valsartan
80 mg + hydrochlorothiazide 12.5 mg daily), and 398/417
(95.4%) amlodipine combination (valsartan 80mg + amlodipine
5 mg daily); 11 participants in the combination arm (all early
study withdrawals) did not have their combination treatment
selected at randomisation. In the next six weeks, 108 (32%),
118 (52%), and 207 (52%) of these participants, respectively,
had progressed to the next level treatment as per study protocol.
At baseline in the usual care group, 367 (70.0%) participants
were still receiving valsartan 80 mg/day and 67 (12.8%) were
receiving the increased dose of 160 mg/day. By study
completion (based on last prescribed treatment) a greater
proportion of participants in the usual care group (n=227) than
intervention group (n=154) were prescribed monotherapy (43.3
v 14.8%) and fewer were prescribed combination (217 (41.4%)
v 609 (58.7%)) or triple (21 (4.1%) v 155 (14.9%)
antihypertensive therapy. Alternatively, prescription resistance
with deviation from the management protocol was evident in
360 participants (34.7%): most deviations (>90%) involved
general practitioners not up-titrating antihypertensive treatment
to achieve one of the two lower blood pressure targets.
Primary endpoint: individualised blood
pressure control
On an intention to treat basis, there was an 8.8% absolute
difference in the primary endpoint in favour of the intervention
group, with 358/988 (36.2%) participants in the intervention
arm achieving their individual blood pressure target compared
with 138/504 (27.4%) in the usual care arm: adjusted relative
risk 1.28 (95% confidence interval 1.10 to 1.49, P=0.0013).
Table 2 shows absolute blood pressure values (with change in
blood pressure from baseline) and overall pattern of blood
pressure control for both groups during progressive visits.
Overall, 627/988 (63.5%) participants in the intervention group
comparedwith 272/504 (54.0%) in the usual care group achieved
the classic blood pressure target of ≤140/90 mm Hg. This
represents an absolute difference of 9.5% in favour of the
intervention group: relative risk 1.18 (95% confidence interval
1.07 to 1.29, P<0.001).
Secondary endpoint: change in blood
pressure
Clinically important falls in mean and systolic blood pressure
were observed in both groups during the 26 weeks of follow-up,
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with a lower diastolic and systolic blood pressure value recorded
after randomisation in 311 (59.4%) participants in the usual
care group comparedwith 719 (69.3%) in the intervention group.
Individualised control of blood pressure showed an inverse
gradient; lower rates of achieving the blood pressure target were
associated with more stringent targets (P<0.001) but better rates
of control throughout in the intervention group. During study
follow-up, mean blood pressure changed (randomisation to
endpoint blood pressure) from 150 (SD 17)/88 (SD 11) mmHg
to 136 (SD 15)/81 (SD 10) mm Hg in the intervention group
compared with 149 (SD 17)/87 (SD 11) mm Hg to 139 (SD
15)/82 (SD 11)mmHg in the usual care group (table 2); adjusted
mean reduction in blood pressure 13.2 (95% confidence interval
12.3 to 14.2) mmHg and 7.7 (7.1 to 8.3) mmHg compared with
10.1 (8.8 to 11.3) mm Hg and 5.5 (4.7 to 6.2) mm Hg in favour
of intervention (P<0.001). In those who completed the 26 weeks
of follow-up (186 (SD 20) days) the equivalent reduction in
blood pressure was also in favour of the intervention (P<0.001):
adjusted mean reduction in blood pressure 14.6 (13.7 to 15.6)
mm Hg and 8.2 (7.6 to 8.8) mm Hg compared with 10.4 (9.1 to
11.7) mmHg and 5.6 (4.7 to 6.4) mmHg. The intervention was
associated with greater levels of individual blood pressure
control in all three target groups (fig 3⇓). Overall, those assigned
the combination treatment arm of the intervention group had
the highest rate of individual blood pressure control (37.9% for
the endpoint and 42.1% at week 26). Similarly, an analysis of
change in blood pressure from baseline to 26 weeks (n=1323)
according to target group showed consistent benefits of the
intervention (8-12% reduction in systolic blood pressure and
7-14% reduction in diastolic blood pressure) compared with
usual care (6-8% and 5-9%, respectively), with the most gains
in blood pressure reduction achieved through the combination
treatment arm overall (see appendix II in the supplementary
file).
Change in absolute cardiovascular risk
Among the 1141 participants in whom absolute cardiovascular
risk profiles were calculated from baseline to 26 weeks’
follow-up (that is, complete data on profiling both before and
after randomisation), the intervention group had a significantly
greater reduction in risk scores (14.7% (SD 9.3%) to 10.9% (SD
8.0%); −3.7% (SD 4.5%)) than the usual care group (15.0%
(SD 10.1%) to 12.4% (SD 9.4%); −2.6% (SD 4.5%)); the
adjusted mean reduction in risk being in favour of the
intervention group (−1.13%, 95% confidence interval −0.69%
to −1.63%; P<0.001). Overall, the proportion of high risk
participants (>15% absolute risk of an event) in the intervention
group decreased from 41.2% to 25.6% and in the usual care
group from 40.2% to 30.1%.
Safety profile
A total of 1044 adverse events were recorded in 592 (27.1%)
participants during the study run-in phase, with 424 (40.6%)
classified as related to treatment by the treating doctor. Overall,
2184 adverse events were recorded after randomisation, with
2152 occurring among the 1492 participants who had at least
six weeks’ follow-up (see appendix III in the supplementary
file for a summary of the adverse events). This included 196
(57.8%) participants allocated to the monotherapy arm and 355
(54.7%) to the combination therapy arm; this compared with
246 (48.8%) participants in the usual care group. Of the adverse
events after randomisation, 543 (24.9%) were classified as
related to treatment, with 422 (0.41/participant) occurring in
the intervention arm and 121 (0.23/participant) in the usual care
arm (table 3⇓). The three most common adverse events after
randomisation attributed to study treatment were dizziness
(including postural hypotension, 86 events), peripheral oedema
(79 events), and fatigue or lethargy (46 events). The rate of
dizziness (0.07 v 0.03 adverse events/participant) and oedema
(predominantly peripheral oedema, 0.06 v 0.03 adverse
events/participants) was highest in the intervention group
overall, andmost common in the combination arm. One (0.06%)
participant randomised to the intervention group died due to
adenocarcinoma. Post-randomisation, 24 (4.6%) participants in
the usual care group experienced 35 serious adverse events
compared with 37 (3.7%) participants and 57 serious adverse
events in the intervention group (6.7 v 5.6 events/100 patients).
In the usual care and intervention groups, respectively, this
included six and eight events involving admission to hospital
for chest pain/angina pectoris, one (in each group) for acute
myocardial infarction, and four (in each group) for other
cardiovascular events. Overall, due to an adverse event drug
treatment was altered in 82 (7.9%) intervention participants
compared with 10 (1.9%) usual care participants (1.1% v 0.2%,
respectively, were withdrawn by the general practitioner or
voluntarily withdrew.
Discussion
A strategy comprising automated risk profiling plus standardised
guideline based, stepwise drug treatment (initial monotherapy
using an angiotensin receptor blocker or two forms of
combination therapy) and intensified follow-up and treatment
titration, resulted in more participants (absolute difference 8.8%)
with persistent hypertension achieving their individual blood
pressure target at 26 weeks than participants receiving usual
care. Importantly, two thirds of the participants had a history
of persistent hypertension despite receiving a typical range of
antihypertensive treatments, and the remainder were
unresponsive to valsartan monotherapy; one of the most
commonly prescribed antihypertensive agents globally. The
study population had an average five year risk of a major
cardiovascular event of over 15% and therefore represented the
more difficult end of the spectrum of people with hypertension
managed in primary care. The detailed clinical profiling at study
entry and general practitioners’ access to the computer assisted
treatment protocol may explain the large, clinically significant,
reductions in blood pressure in both groups (mean change >13/7
mm Hg in the intervention group and >10/5 mm Hg in the
control group). The combined application of more intensive
follow-up and drug treatment is reflected in greater use of
combination therapies (prescribed as single pills) and
progressive reductions in blood pressure between six and 26
weeks in the intervention group. These incremental benefits in
blood pressure control largely influenced more favourable
absolute cardiovascular risk scores in participants assigned to
intervention, with just over one third in this group achieving
their individual blood pressure target and around two thirds the
classic blood pressure target of ≤140/90 mm Hg; the same
advocated by NICE in the United Kingdom.4 If further
adjustment is made for those who initially responded to more
intensive management and monotherapy using an angiotensin
receptor blocker at study run-in (apportioning equal success and
failure to both treatment groups), this figure increases from 64%
to 72%. An important trade-off for what could be considered
to be modest absolute differences in absolute blood pressure
levels between groups was the small increase in the proportion
of participants who withdrew from the study (1.1% v 0.2%) and
more frequent (7.9% v 1.9%) modification of treatment due to
adverse events in the intervention group.
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Strengths and limitations of this study
The intervention directly addressed the difficult challenge of
optimising blood pressure control in a real world general practice
setting using commonly prescribed forms of antihypertensive
agents. This is a major concern for countries with aging
populations, where hypertension related heart and
cerebrovascular disease is a growing problem.14 By necessity,
this pragmatic study used an open label design (with no blinding
of treatment pathways or blood pressuremeasurements possible)
with scheduled visits that varied according to clinic schedules
and prescribed drug treatment and relied on the mainstream
healthcare system in Australia. The broader application and
possible impact of the intervention (particularly in other
healthcare systems) therefore needs to be interpreted cautiously.
However, we do have preliminary projections (data not shown)
based on national primary care data in Australia, that even the
modest absolute differences in blood pressure between groups
would have a potentially large impact (as reflected in the primary
endpoint and absolute risk differences) among the thousands of
Australians who don’t achieve their blood pressure targets each
year. The selection of valsartan based treatments, rather than
an open choice of agents, was predicated on the ability to
standardise drug treatment in the intervention arm with precise
up-titration pathways and to determine the potential impact of
monotherapy versus combination therapy on short (six weeks)
and longer term (26 weeks) blood pressure control. Certainly
these agents targeting the renin-angiotensin system represent
some of the most commonly applied in clinical practice
internationally, and the treatment regimen is broadly consistent
with the NICE guidelines (phase 3) for people with hypertension
who do not respond to initial monotherapy.4 We deliberately
chose individual randomisation rather than a cluster design to
increase the robustness of our findings for two reasons. Firstly,
we wanted to avoid potential imbalances between the groups
when using a larger unit of randomisation (that is, a general
practice). Secondly, we wanted to expose participants with the
same general practitioner to the two study groups (and indeed
treatment arms within the intervention group) to truly determine
if the programme would alter blood pressure management at
the individual level. Although this resulted in almost inevitable
cross contamination of more intensive management in the usual
care group (with clinically significant reductions in blood
pressure in both groups), we were still able to show that the
intervention was associated with incremental benefits in blood
pressure control (8.8% absolute difference in the primary
endpoint) tempered bymore adverse events requiring adjustment
of treatment. Alternatively, unblinded blood pressures in the
clinic reported by general practitioners (albeit using a
standardised protocol and automated monitors) may have
resulted in an element of bias, the recruitment of participants
with so called white coat hypertension,15 or an observed
regression to the mean (blood pressure) over time. Wherever
possible we minimised these factors by implementing a 28 day
standardised treatment and blood pressure monitoring run-in
phase, applying a standardised protocol for blood pressure
monitoring and undertaking independent clinical auditing for
data verification. Whether these data would be reproduced if
we had studied 24 hour ambulatory blood pressure or home
blood pressure measurements is open to debate.16 However, at
this time current guidelines are based on clinic blood pressure
measurements and the study reflects current clinical practice in
most countries. We do not know as of yet if the reduction in
absolute cardiovascular risk will be maintained or result in fewer
cardiovascular events in the future. Notably, 4% of randomised
participants did not have an endpoint blood pressure recorded
and were excluded from endpoint analyses. For these 70
participants, retrospective analyses where either the randomised
blood pressure was brought forward (relative risk 1.27, 95%
confidence interval 1.09 to 1.48) or the change in blood pressure
was imputed according to study group and blood pressure target
(1.26, 1.08 to 1.46) did not substantially alter the primary
endpoint results (P<0.001 for both comparisons). The general
practitioners were reluctant to try to meet the more aggressive
guideline targets for blood pressure reduction and in almost
15% of cases opted for a more lenient target, in effect making
the task of achieving control easier.
Supporting the evidence in favour of
structured primary care
Consistent with data from other countries such as the United
States,2we have strong evidence from community based studies,9
preliminary data from the pilot stages of the VIPER-BP study,13
and data from the usual care group, that present approaches to
the management of hypertension have meant that the “rule of
halves” still applies—that is, close to 50% of those treated for
hypertension in primary care remain hypertensive. Regardless
of recent suggestions that lower blood pressure targets in high
risk people should be reassessed,8 there is still clear evidence
from population cohorts2 andmeta-analyses of clinical trial data3
that lowering blood pressure (even by the modest, incremental
margins associated with more intensive management) will
noticeably attenuate the rates of stroke and other cardiovascular
disease. In support of a more aggressive approach to the
management of hypertension, retrospective results from both
the Valsartan Antihypertensive Long-term Use Evaluation
trial17 18 and Avoiding Cardiovascular Events in Combination
Therapy in Patients Living with Hypertension19 trial suggest
there are advantages to achieving early blood pressure control
and that application of combination treatments are more likely
to achieve this goal. The intervention in the current study
brought all these elements together, with more than double (81%
v 40%) the proportion of intervention participants receiving
combination therapy compared with monotherapy at 26 weeks.
To our knowledge this study (incorporating a combined drug
and disease management approach to the management of blood
pressure facilitated by a standardised computer support program)
is one of the largest studies of its kind. Although there have
been several large hypertension trials with a major focus on the
efficacy of different combinations of drug treatment20 and
specific studies of algorithm based strategies,10 12 there are few
large scale, multicentre studies that have specifically compared
a structured and intensive care approach with usual care in
achieving better blood pressure control based onmore stringent
risk based targets in patients with persistent hypertension
managed in primary care. The results of the present study
therefore strengthen the conclusions of a recently updated
Cochrane review recommending a stepped and intensive
approach to the management of hypertension in primary care;
particularly in those participants who remain hypertensive
despite initial treatment.10 In particular, the results complement
the findings of a similarly large scale (cluster randomised
design) Canadian study21 of a simplified treatment algorithm in
primary care that showed a 12% absolute difference (65% v
53%) in favour of the study intervention. Notable differences
were the low proportion of participants requiring more stringent
blood pressure targets (about 15%) and the lack of initial
standardised care that in the present study resulted in almost
one in five participants achieving early blood pressure control
during the study run-in phase. Thus our randomised cohort
represented a more “challenging” group of patients with
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hypertension. It could be argued that we have now reached a
similar stage of developing the evidence in favour of more
structured care (that is, beyond a purely drug related approach)
to optimise blood pressure management in primary care to that
of heart failure management programmes; where head to head
trials of different forms of structured care are being undertaken22
to refine (rather than to establish) a new level of best clinical
practice.
Clinical implications
Several important issues highlighted by this pragmatic study
involving more than 250 general practitioners are relevant to
clinical practice guidelines and health policy in Australia and
other high income countries where hypertension remains a
problem. Firstly, the initial application of standardised
monotherapy (valsartan 80 mg/day) in a structured approach,
irrespective of previous treatment, was immediately successful
in controlling a large group of people with hypertension and
should be considered when reviewing primary endpoint data.
Given its size and direct relevance to other high income
countries, the study is likely to influence future blood pressure
guidelines, particularly informing debate around the attainment
of lower blood pressure targets, whether these lower targets are
truly achievable, and the role of prescription resistance11 in
limiting what is meant by “truly achievable.” Only a small
proportion of participants in the most stringent blood pressure
group achieved this target despite the intensive approach with
three or more drugs applied in the intervention. Given the nature
of the study, these data are likely to reflect real world blood
pressure management, and any consideration of retaining more
stringent blood pressure targets (particularly if low values are
proved to be unnecessary in those with pre-existing
cardiovascular disease8) has to consider the impact of at least
aiming for lower blood pressure to achieve values ≤140/90 mm
Hg. Both an overall reluctance by general practitioners to
prescribe higher doses of combination or triple treatment and
individual patient factors seem to have prevented more
participants from reaching their individual blood pressure target
and the classic target of ≤140/90mmHg. It is worth highlighting
that in the Australian healthcare system, subsidised drug
treatment ensures that costs are not usually a barrier to the
application of more aggressive treatment.
Although the absolute difference in change in blood pressure
between the groups might be considered modest, they not only
contributed to more people achieving the primary endpoint in
the intervention group but also favourably altered both the
absolute risk of future cardiovascular events (a clinically
meaningful 1% difference in mean scores between groups) and
the relative risk reduction of future coronary artery disease (−6%
difference in mean risk) and strokes (−11% difference) in favour
of the intervention (data not shown). The expected trade-off
between more intense blood pressure control and an increase
in adverse events occurred, with more participants in the
intervention group withdrawn on this basis (1.1% v 0.2%) or
requiring active change to their treatment (7.9% v 1.9%). This
needs to be carefully considered against the overall difference
(8.8% in favour of the intervention group) in the primary
endpoint. Overall, the number and frequency of adverse events
was consistent with the nature and size of the patient cohort and
the drugs being prescribed.Whereas there seems to be a gradient
in blood pressure control according to the amount of drug
treatment (with greater control achieved in those assigned to
immediate combination therapy at randomisation), spending
additional clinical time (>1 hour over six months) with
participants probably also contributed. Such a conclusion is
consistent with previous systematic reviews andmeta-analyses,10
and the patient centred approach advocated by contemporary
guidelines.4 6 7 This observation is further strengthened by the
initial response to the run-in phase of the study where
information on non-drug measures was provided with only low
dose monotherapy (19% blood pressure control) and substantial
anecdotal evidence from participants who appreciated the
“beyond pharmacological” approach to their management.
Future challenges
Despite noticeable reductions in blood pressure in both arms of
the VIPER-BP study, a relatively small proportion of
participants achieved thesemore stringent blood pressure targets;
the classic target of ≤140/90 mm Hg being far more attainable.
Given the intensity of the intervention and facilitated pathways
to higher doses of combination antihypertensive treatment, these
data highlight critical questions around the application of more
stringent blood pressure targets in high risk people—that is,
those with established cardiovascular disease or renal disease.
The results are particularly relevant to clinicians when clinical
guidelines and health policies seek to apply expert
recommendations that may not be truly achievable. As such,
these data may prompt a re-evaluation of blood pressure targets
to reflect real world limitations for doctors managing
hypertension in the busy and often complex primary care setting.
The results also point to major patient related barriers to
eviscerating blood pressure targets as even with best practice
drug prescription and clinical support most participants still did
not achieve the primary endpoint of blood pressure
recommended by current guidelines.Most importantly, however,
we have shown that a structured blood pressure management
approach (computer assisted) results in higher blood pressure
control rates in a primary care setting. As always, the challenge
will be to implement this strategy into wider clinical practice
by further analysing what did and did not work in this and other
similar studies and how best to deliver pragmatic tools to
facilitate the optimal management of blood pressure in the
primary care setting.
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What is already known on this topic
Hypertension is the leading risk factor for cardiovascular disease worldwide and one of the most common conditions managed in primary
care
Despite effective drug treatments, a substantial proportion of affected people remain above their ideal blood pressure target
Systematic reviews suggest that additional gains in blood pressure control can be attained with a more intensive structured approach
to management
What this study adds
Compared with usual care, an intensive, structured programme for blood pressure control in primary care was associated with an 8.8%
increase in the proportion of participants achieving individual targets and 9.5% increase in those achieving the classic target of ≤140/90
mm Hg
Despite parallel reductions in absolute cardiovascular risk, achieving more stringent blood pressure targets remains a challenge
Modification of treatment owing to adverse events was more common in the intervention group than usual care group (7.9% v 1.9%)
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Tables
Table 1| Baseline characteristics according to group randomisation (n=1562). Values are numbers (percentages) of participants unless
stated otherwise
Intervention group
Usual care group (n=524)Characteristics Combination therapy arm (n=678)Monotherapy arm (n=360)Total (n=1038)
418 (61.7)222 (61.7)640 (61.7)323 (61.6)Men
59.1 (11.6)59.5 (12.3)59.2 (11.8)59.3 (12.4)Mean (SD) age (years)
Clinical profile:
439 (64.7)253 (70.3)692 (66.7)353 (67.4)Previous hypertension
58 (8.6)35 (9.7)93 (9)38 (7.3)Heart disease
126 (18.6)69 (19.2)195 (18.8)106 (20.2)Type 2 diabetes
119 (17.6)64 (17.8)183 (17.6)93 (17.7)Proteinuria
169 (24.9)73 (20.3)242 (23.3)127 (24.2)Microalbuminuria
88.9 (20.4)86.7 (18.4)88.2 (19.7)87.8 (19.6)Mean (SD) eGFR (mL/min/1.73m2)
58 (8.6)35 (9.7)93 (9)38 (7.3)All cardiovascular disease
201 (29.6)104 (28.9)305 (29.4)132 (25.2)
No cardiovascular disease or end organ
damage
52 (7.7)23 (6.4)75 (7.2)36 (6.9)ECG evidence of LVH
Blood pressure profile (mm Hg):
149.9 (16.8)150.1 (17.0)150.0 (16.9)149.2 (16.6)Mean (SD) systolic
88.6 (10.9)88.0 (10.6)88.4 (10.8)87.4 (11.4)Mean (SD) diastolic
Target blood pressure (mm Hg):
198 (29.2)106 (29.4)304 (29.3)145 (27.7)≤140/90
367 (54.1)190 (52.8)557 (53.7)286 (54.6)≤130/80
113 (16.7)64 (17.8)177 (17.1)93 (17.7)≤125/75
eGFR=estimated glomerular filtration rate; ECG=electrocardiography; LVH=left ventricular hypertrophy.
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Table 2| Mean systolic and diastolic blood pressure and absolute change from baseline by study visits. Values are means (standard
deviations) unless stated otherwise
Intervention group
Usual care groupMeasures at study visits Combination therapy armMonotherapy armAll
n=678n=360n=1038n=524Baseline:
149.9 (16.8)150.1 (88.0)150.0 (16.9)149.2 (16.6)Systolic blood pressure
88.6 (10.9)17.0 (10.6)88.4 (10.8)87.4 (11.4)Diastolic blood pressure
————No (%) achieving blood pressure target*
n=626n=319n=945n=479Week 6:
140.0 (15.3)144.6 (16.8)141.5 (16.0)142.1 (15.2)Systolic blood pressure
83.1 (10.3)84.9 (10.4)83.7 (10.4)83.9 (10.8)Diastolic blood pressure
−9.9 (−5.5)−5.1 (−3.2)−8.3 (−4.7)−7.2 (−3.6)Change in blood pressure from baseline*
166 (26.5)57 (17.9)223 (23.6)97 (20.3)No (%) achieving blood pressure target*
n=578n=294n=872Week 10:
137.8 (15.2)143.8 (17.7)139.8 (16.3)—Systolic blood pressure
81.9 (10.9)84.3 (11.1)82.71 (1.0)—Diastolic blood pressure
−12.1 (−6.5)−6.1 (−3.5)−10.1 (−5.5)—Change in blood pressure from baseline*
181 (31.3)66 (22.5)247 (28.3)—No (%) achieving blood pressure target*
n=550n=281n=831Week 14:
134.7 (14.3)139.4 (15.7)136.3 (14.9)—Systolic blood pressure
80.0 (10.1)81.3 (10.7)80.410.4—Diastolic blood pressure
−14.9 (−8.4)−10.5 (−6.5−13.4 (−7.7)—Change in blood pressure from baseline*
215 (39.1)80 (28.5)295 (35.5)—No (%) achieving blood pressure target*
n=553n=276n=829Week 18:
134.6 (14.6)136.5 (15.3)135.2 (14.8)—Systolic blood pressure
79.9 (10.1)79.8 (10.7)79.9 (10.3)Diastolic blood pressure
−15.1 (−8.5)13.2 (−7.9)−14.5 (−8.3)—Change in blood pressure from baseline*
226 (40.9)104 (37.7)330 (39.8)—No (%) achieving blood pressure target*
n=568n=289n=857n=466Week 26:
133.6 (13.3)136.5 (15.6)134.6 (14.2)138.8 (14.9)Systolic blood pressure
79.6 (9.7)80.4 (10.5)79.9 (10.0)82.0 (10.5)Diastolic blood pressure
−16.1 (−8.9)−10.6 (−7.6)−15.2 (−8.5)−10.5 (−5.3)Change in blood pressure from baseline*
239 (42.1)104 (36.0)343 (40.0)129 (27.7)No (%) achieving blood pressure target*
n=649n=339n=988n=504Endpoint blood pressure†:
135.1 (14.2)138.0 (17.0)136.1 (15.3)139.1 (15.0)Systolic blood pressure
80.2 (9.9)81.3 (10.8)80.6 (10.2)82.3 (10.5)Diastolic blood pressure
−14.6 (−8.4)−11.8 (−6.8)−13.7 (−7.8)−10.2 (−5.2)Change in blood pressure from baseline*
246 (37.9)112 (33.0)358 (36.2)138 (27.4)No (%) achieving blood pressure target*
*Calculated for those only with data recorded at each time point and on an intention to treat basis.
†Calculated from last recorded data after randomisation.
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Table 3| Number of adverse events by system organ class and relation to study treatment derived from before randomisation (n=2185) and












2907221213564111078113550424620Total No of adverse
events
0 (0)2 (0.3)0 (0)0 (0)0 (0)2 (0.2)0 (0)2 (0.4)1 (0.2)4 (0.6)
Blood and lymphatic
system
68 (23.4)95 (13.2)34 (28.1)32 (9)102 (24.8)127 (11.8)23 (20.4)88 (16)100 (23.6)74 (11.9)Cardiac
1 (0.3)0 (0)0 (0)0 (0)1 (0.2)0 (0)0 (0)0 (0)0 (0)0 (0)
Congenital, familial,
and genetic
1 (0.3)15 (2.1)4 (3.3)5 (1.4)5 (1.2)20 (1.9)1 (0.9)11 (2)4 (0.9)7 (1.1)Ear and labyrinth
0 (0)1 (0.1)0 (0)0 (0)0 (0)1 (0.1)0 (0)2 (0.4)0 (0)0 (0)Endocrine
6 (2.1)14 (1.9)2 (1.7)11 (3.1)8 (1.9)25 (2.3)1 (0.9)15 (2.7)2 (0.5)14 (2.3)Eye
28 (9.7)58 (8)16 (13.2)42 (11.8)44 (10.7)100 (9.3)15 (13.3)32 (5.8)67 (15.8)81 (13.1)Gastrointestinal




0 (0)2 (0.3)0 (0)1 (0.3)0 (0)3 (0.3)0 (0)1 (0.2)0 (0)1 (0.2)Hepatobiliary
0 (0)6 (0.8)0 (0)3 (0.8)0 (0)9 (0.8)0 (0)1 (0.2)0 (0)3 (0.5)Immune system
2 (0.7)116 (16.1)0 (0)45 (12.6)2 (0.5)161 (14.9)1 (0.9)86 (15.6)2 (0.5)78 (12.6)
Infections and
infestations




6 (2.1)14 (1.9)2 (1.7)8 (2.2)8 (1.9)22 (2)1 (0.9)8 (1.5)2 (0.5)13 (2.1)Investigations
1 (0.3)9 (1.2)3 (2.5)11 (3.1)4 (1)20 (1.9)2 (1.8)10 (1.8)3 (0.7)10 (1.6)
Metabolism and
nutrition
19 (6.6)68 (9.4)7 (5.8)38 (10.7)26 (6.3)106 (9.8)9 (8)58 (10.5)29 (6.8)49 (7.9)
Musculoskeletal and
connective tissue






26 (9)53 (7.3)13 (10.7)27 (7.6)39 (9.5)80 (7.4)18 (15.9)37 (6.7)73 (17.2)67 (10.8)Nervous system
7 (2.4)13 (1.8)3 (2.5)17 (4.8)10 (2.4)30 (2.8)5 (4.4)15 (2.7)26 (6.1)21 (3.4)Psychiatric
3 (1)12 (1.7)3 (2.5)2 (0.6)6 (1.5)14 (1.3)0 (0)11 (2)3 (0.7)12 (1.9)Renal and urinary
2 (0.7)10 (1.4)2 (1.7)4 (1.1)4 (1)14 (1.3)3 (2.7)6 (1.1)2 (0.5)3 (0.5)
Reproductive
system and breast




11 (3.8)45 (6.2)3 (2.5)21 (5.9)14 (3.4)66 (6.1)0 (0)21 (3.8)19 (4.5)28 (4.5)
Skin and
subcutaneous tissue
0 (0)0 (0)0 (0)1 (0.3)0 (0)1 (0.1)0 (0)0 (0)0 (0)0 (0)
Social
circumstances
0 (0)12 (1.7)0 (0)4 (1.1)0 (0)16 (1.5)1 (0.9)10 (1.8)0 (0)13 (2.1)
Surgical and
medical procedures
10 (3.4)14 (1.9)4 (3.3)4 (1.1)14 (3.4)18 (1.7)5 (4.4)8 (1.5)17 (4)15 (2.4)Vascular
2 (0.7)0 (0)0 (0)0 (0)2 (0.5)0 (0)3 (2.7)0 (0)3 (0.7)0 (0)Unknown
41 adverse events with unknown incident date, not presented in table.
*Defined as highest level according to Medical Dictionary for Regulatory Activities (MedDRA, www.meddramsso.com/index.asp), which contains medical terminology
used to classify information on adverse events associated with use of biopharmaceuticals and other medical products (for example, medical devices and vaccines).
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Coding these data to a standard set of MedDRA terms allows health authorities and the biopharmaceutical industry to more readily exchange and analyse data
related to the safe use of medical products.
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Figures
Fig 1 Summary of study timelines
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Fig 2 Flow of participants through study
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;345:e7156 doi: 10.1136/bmj.e7156 (Published 20 November 2012) Page 15 of 16
RESEARCH
Fig 3Change in systolic and diastolic blood pressure according to individual blood pressure target at randomisation (n=1492).
On an adjusted basis, participants assigned to intervention were significantly more likely to achieve their target at the two
higher blood pressure target levels
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